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Damage of lens epithelial cells (LECs) has been implicated in cataract formation. The aim of this study was to investigate the
protective eﬀect of KIOM-79, a combination of four plant extracts, on LECs. We examined the levels of advanced glycation
end products (AGEs), nuclear factor-kappaB (NF-κB) activation and inducible nitric oxide synthase (iNOS) expression in LECs
during cataract development using the Zucker diabetic fatty (ZDF) rat, an animal model of type 2 diabetes. KIOM-79 was orally
administered by gavage to ZDF rats once a day for 13 weeks. Apoptosis was detected by TUNEL assay, and NF-κB activation and
iNOS expression were studied by southwestern histochemistry and immunohistochemistry, respectively. In diabetic cataractous
lenses,TUNEL-positiveLECsweremarkedlyincreased20-fold,andAGEswerehighlyaccumulated(2.7-fold)inLECs.Inaddition,
both NF-κB activation, and iNOS expression were signiﬁcantly enhanced 3- to 5-fold, respectively, compared to levels found in
normal ZL rats. However, the administration of KIOM-79 delayed the development of diabetic cataracts and prevented LEC
apoptosis (70%) through the inhibition of AGEs, NF-κB-activation and iNOS expression. These observations suggest that KIOM-
79 is useful in inhibiting diabetic cataractogenesis and acts through an antiapoptotic mechanism to protect LECs from injury.
1.Introduction
Cataract, characterized by cloudiness or opaciﬁcation of
the eye lens, is the leading cause of blindness worldwide.
Although the pathogenesis of diabetic cataract is not known,
various biochemical pathways, such as the polyol pathway,
the generation of advanced glycation end products (AGEs)
and oxidative stress, have been implicated [1]. Recently, the
damage of lens epithelial cells (LECs), induced by chronic
hyperglycemia, is considered to be important in perturbing
lens homeostasis [2]. The eye lens contains only a single layer
of epithelial cells in its anterior surface. LECs are thought to
protect underlying ﬁbers from injury [3] and maintain the
transparency of the lens [4]. Thus, the damage of this cell
might be linked to cataractogenesis.
AGEs are sugar-derived, irreversible protein modiﬁca-
tions that have been implicated in the pathogenesis of
diabetic complications [5]. It was reported that AGEs
enhance apoptosis of retinal pericytes, corneal endothelial
cells, neuronal cells, and renal mesangial cells through
increasing oxidative stress or via induced expression of pro-
apoptotic cytokines [6–8]. Furthermore, AGEs induce a
dose-dependent activation of nuclear factor-kappaB (NF-
κB) in LECs in vitro [9]. The activation of NF-κBm i g h t
play an important role in modulating the function of LECs
[10, 11]. NF-κB activation due to ultraviolet irradiation
induces apoptosis in LECs [11]. NF-κBa c t i v a t i o ni no c u l a r
tissue also induces both the loss of retinal pericytes [12]a n d
retinal capillary cell death [13]. Activated NF-κB binds with
target DNA in cellular nuclei, which activates the gene for
induction of cellular death.
Nitric oxide (NO) is a signaling molecule that mediates
a variety of physiological processes, including neurotrans-
mission, vasodilation, and host cell defense. The expression
of inducible nitric oxide synthase (iNOS) is induced by
cytokines, AGEs, and NF-κB[ 14, 15], and its induction
results in the release of excessive amounts of NO [16, 17]. In
several ocular diseases, including uveitis, retinitis, glaucoma,
and cataract, the alteration of iNOS expression has been
reported [18–21]. In addition, in vitro cataract formation,2 Evidence-Based Complementary and Alternative Medicine
generated by high levels of glucose, is inhibited by a nitric
oxide synthase inhibitor [22]. Therefore, these ﬁndings
suggest that the inhibition of AGEs, NF-κB activation,
and iNOS expression represent potential therapies for the
prevention of LEC injury and diabetic cataractogenesis.
KIOM-79 is a mixture of the 80% ethanol extract
of parched Puerariae radix, gingered Magnoliae cortex,
Glycyrrhizae radix, and Euphorbiae radix. These herbs
are used in traditional Korean medicine for a variety of
medical purposes, including diabetes [23]. Our previous
work showed that KIOM-79 prevented the development
of diabetic nephropathy in streptozotocin-(STZ-) induced
type 1 diabetic rats [24] and nonobese type 2 diabetic
Goto-Kakizaki rats [25]. In addition, previous studies have
reported that KIOM-79 treatment shows a strong inhibitory
eﬀect on AGE formation in vitro [24] and inhibits STZ-
induced apoptosis of the pancreatic betacells [26]. Recently,
KIOM-79wasshowntopreventapoptosisofretinalganglion
cells in diabetic db/db mice without aﬀecting blood glucose
[27]. Despite the various eﬀects of KIOM-79 on diabetic
complications, the eﬀect on LEC injury and diabetic cataract
is limited. Therefore, in this study, we evaluated the eﬀect
of KIOM-79 treatment on LEC injury and cataractogenesis
in the Zucker diabetic fatty (ZDF) rat, an animal model of
type 2 diabetes. Based on the above-mentioned therapeutic
targets, we speciﬁcally evaluated the ability of KIOM-79
to inhibit AGE accumulation, NF-κB activation and iNOS
expression in LECs and identiﬁed an anti-apoptotic property
of KIOM-79.
2.MaterialsandMethods
2.1. Preparation of KIOM-79. KIOM-79 was prepared as
previously described in [23, 27]. Brieﬂy, the cortex of
Magnolia oﬃcinalis, radix of Pueraria lobata, radix of
Glycyrrhiza uralensis, and radix of Euphorbia pekinensis
were collected from plants obtained from Gamsuk Province
(China). Magnoliae cortex (100g) was simmered with 3g
of Zingiberis rhizoma for 60 minutes. Puerariae radix
(100g) was stir-roasted at 75◦C for 45 minutes. Equal
amounts of gingered Magnoliae cortex, parched Puerariae
radix, Glycyrrhizae radix, and Euphoriae radix were mixed,
pulverized, extracted in 80% ethanol for one week at
room temperature, concentrated with a rotary evaporator,
and lyophilized. The entire procedure was repeated four
times.
2.2. Standardizationof KIOM-79. Identiﬁcation of the major
compounds in KIOM-79 was determined by high perfor-
mance liquid chromatography (HPLC, Agilent 1200 HPLC
system, Agilent, CA, USA). A Spherex C-18 analytical
column (250 × 4.6mm, 5.0μm, Phenomenex, CA, USA)
was used with the mobile phase consisted of acetonitrile
(A) and 0.1% acetic acid in water (B). The mobile phase
gradient elution was programmed as follows: 95–70% B (0–
30 minutes), 70–40% B (30–40 minutes), 40–0% B (40-
45 minutes), and 100% A (45–50 minutes). The column
temperature was maintained at 30◦C, ﬂow rate set at
1ml/minutes, and sample injection volume was set at 10μl.
2.3. Animals and Experimental Design. Male 6-week-old
ZDF rats (ZDF/Gmi-fa/fa) and Zucker lean (ZL) counter-
parts (ZDF/Gmi-lean) were purchased from Charles River
Laboratory (Waltham, MA, USA) and acclimated for 1
week prior to the study. Rats were individually housed in
plastic cages and maintained at 24◦C ± 2◦C with a 12-hour
light:dark cycle and received a diet of Purina 5008 (Ralston
Purina, St. Louis, MO, USA) and tap water ad libitum.R a t s
were divided into 3 groups of 8 rats, according to their initial
blood glucose concentration as follows: (1) normal ZL rats,
(2) vehicle-treated ZDF rats and (3) ZDF rats treated with
KIOM-79 (50mg/kg body weight). The dosage of freeze-
dried powder was calculated based on the minimum human
equivalent dosage of raw herbs. KIOM-79 was dissolved in
distilled water and administered daily by oral gavage for
13 weeks. In normal ZL rats and vehicle-treated ZDF rats,
water was given orally for 13 weeks. Blood glucose levels and
body weights were monitored consecutively, and glycated
hemoglobin was determined by a commercial kit (Unimate
HbA1c, Roche Diagnostics, Mannheim, Germany). All pro-
cedures involving rats were approved by the Korea Institute
of Oriental Medicine Institutional Animal Care and Use
Committee.
2.4. Analysis of Cataract Development. Following thirteen
weeks of treatment, eyes were enucleated under deep
anesthesia, following an intraperitoneal injection of pento-
barbital sodium (30mg/kg body weight). The lenses were
excised from eyeballs under an optical microscope and
transferred onto 6-well plates each containing 5ml of a
saline solution. Lens opacity was then measured under an
optical microscope. Score of lens opacity is determined as
follows according to the classiﬁcation of Ao et al. [28]: 0,
clear normal lens; 1, peripheral vesicles; 2, peripheral vesicles
and cortical opacities; 3, diﬀuse central opacities; 4, matured
nuclear cataract.
2.5.ApoptosisAssay. TUNELassayswereperformedwiththe
DeadEnd apoptosis detection system (Promega, Madison,
WI, USA), according to the manufacturer’s instructions.
Apoptotic cells were detected with peroxidase-conjugated
streptavidin in the lens section. For quantitative analysis,
TUNEL-positive nuclei were then counted.
2.6. Immunohistochemical Staining. Immunohistochemistry
was performed as previously described in [29]. Antibod-
ies were mouse anti-AGEs (6D12, Cosmo bio, Tokyo,
Japan) and rabbit anti-iNOS (Cell Signaling, MA, USA).
The 6D12 antibody recognizes both Nε-(carboxymethyl)
lysine-(CML-) and Nε-(carboxyethyl) lysine-(CEL-) protein
adduct as epitopes. For detection of AGEs and iNOS, the
sectionswereincubatedwiththeLSABkit(DAKO,CA,USA)
a n dvi s u a l i z edb y3 , 3  -diaminobenzidine tetrahydrochloride.
For morphometric analysis, the immunoreactive intensity
per unit area (0.32mm2) in a total of 5 ﬁelds was determined
using Image J software (NIH).
2.7. Immunoﬂuorescence Staining. Immunoﬂuorescence
staining was performed on the lens sections. The lensEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: Analysis of lens opacity. Representative images of lenses
in each group. Lens opacity was analyzed (score 0 to 4) from each
lens from a normal Zucker lean rat (ZL), Zucker diabetic fatty rat
(ZDF), and ZDF rat treated with KIOM-79 (KIOM-79). All data
are expressed as means ± SE, n = 8. ∗P<. 01 versus vehicle-treated
ZDF rats.
sections were incubated with rabbit anticleaved caspase-3
antibody (Cell Signaling, MA, USA). The sections were then
incubated with tetramethyl rhodamine isocyanate-(TRITC-)
conjugated goat antirabbit IgG (Santa Cruz, CA, USA). The
intensity of the ﬂuorescence was analyzed in ﬁve randomly
selected mm2 areas using Image J software (NIH).
2.8. Western Blotting Analysis. Whole lenses from each
group were homogenized in RIPA buﬀer (20mM Tris-HCl
pH 7.4, 1.0% Triton X-100, 150mM NaCl, 100μMl e u -
peptin, 100μM aprotinin, 1mM EDTA, and 1mM EGTA).
T h ei n s o l u b l em a t e r i a l sw e r er e m o v e db yc e n t r i f u g a t i o n .
Proteins were then separated by SDS–polyacrylamide gel
electrophoresis and transferred to nitrocellulose membranes
(Biorad,CA,USA).Membraneswereprobedwithanti-AGEs
antibody (Cosmo bio), and then the immune complexes
were visualized with an enhanced chemiluminescence detec-
tion system (ECL; Amersham Bioscience, NJ, USA). Protein
expression levels were determined by analyzing the signals
captured on the nitrocellulose membranes using an image
analyzer (Las-3000, Fuji photo, Tokyo, Japan).
2.9. Southwestern Histochemistry for the Detection of Acti-
vated NF-κB. To localize the NF-κBa c t i v i t yi nl e n s
epithelial cells, in situ southwestern histochemistry was
performed as described by Hernandez-Presa et al. [30].
Table 1: Amounts of puerarin, glycyrrhizin, honokiol, and mag-
nolol in KIOM-79.
Compound Content (mean ± SD, n = 3)
%
Puerarin 4.82 ± 0.05
Glycyrrhizin 2.17 ± 0.04
Honokiol 0.87 ± 0.05
Magnolol 1.69 ± 0.10
Brieﬂy, complementary oligonucleotides containing the NF-
κB binding consensus sequence were synthesized as fol-
lows: 5 -AGTTGAGGGGACTTTCCCAGGC-3 . The probe
was labeled with digoxigenin (DIG oligonucleotide 3 -
end labeling kit, Roche Diagnostics, Mannheim, Ger-
many). Formalin-ﬁxed, paraﬃn-embedded lens sections
were dewaxed, rehydrated, and incubated with 5mM lev-
amisole (Dako) to inhibit endogenous alkaline phosphatase,
and ﬁxed with 0.2% paraformaldehyde for 30 minutes at
28◦C. Sections were subsequently digested with pepsin A
(433U/mg; Sigma), washed twice with buﬀer 1 (10mM
HEPES, 40mM NaCl, 10mM MgCl2, 1mM DTT, 1mM
EDTA, 0.25% BSA, pH 7.4), then with 0.1mg/ml DNAse
I, and ﬁnally washed once with buﬀer 2 (10mM HEPES,
40mM NaCl, 1mM DTT, 10mM EDTA, 0.25% BSA, pH
7.4) to stop the reaction. The labeled probe (100 pM) diluted
in buﬀer 1 containing 0.5mg/ml poly (dI-dC) (Pharmacia
LKB, Piscataway, NJ, USA) was applied overnight at 37◦C.
Afterwashing,sectionswereincubatedfor1hourinblocking
solution (0.01X SSC, 0.01% SDS, 0.03% Tween 20, 0.1 M
maleic acid, 0.15 M NaCl, pH 7.5) and with antidigoxigenin
antibody conjugated with alkaline phosphatase (1:250 in
blocking solution; Roche Diagnostics) 1 hour at 37◦C.
The color reaction was developed using nitroblue tetra-
zolium (NBT, Roche Diagnostics) and 5-bromo-4-chloro-3-
indolylphosphate (BCIP, Roche Diagnostics). The number
of cells positive for NF-κB activation was then counted
with computer-assisted image J software (NIH). As negative
controls, the following were used: (1) absence of probe,
(2) mutant NF-κB probe labeled with digoxigenin, and (3)
competition assays with a 200-fold excess of unlabeled NF-
κB followed by incubation with labeled probe.
2.10. Statistical Analysis. Statistical evaluation of the results
was performed using a one-way analysis of variance
(ANOVA) followed by Tukey’s multiple comparison test
using GraphPad Prism 4.0 software (Graph pad, CA, USA).
3. Results
3.1. HPLC Analysis of KIOM-79. The major components
of KIOM-79 include puerarin, glycyrrhizin, honokiol, and
magnolol. The amounts of puerarin, glycyrrhizin, honokiol,
and magnolol in KIOM-79 were 4.82, 2.17, 0.87, and 1.69%,
respectively (Table 1).4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Apoptosis of LECs. (a) The lens sections from a normal Zucker lean rat (ZL), vehicle-treated ZDF rat (ZDF), and ZDF rat
treated with KIOM-79 (KIOM-79) were stained with a TUNEL kit. Apoptotic LECs (arrow) were observed in vehicle-treated ZDF rats. (b)
Immunoﬂuorescence staining of cleaved caspase-3. Immunoﬂuorescence signals for cleaved caspase-3 (red) were mainly detected in the lens
epithelium of ZDF rats. X400 magniﬁcation. (c and d) Quantitative analysis of TUNEL-positive and cleaved caspase-3-positive cells in LECs.
All data are expressed as means ± SE, n = 8. ∗P<. 01 versus normal ZL rats, #P<. 01 versus vehicle-treated ZDF rats.
3.2. Body Weight, Blood Glucose, and HbA1c Levels. At 21
w e e k so fa g e ,a l lZ D Fr a t sd e v e l o p e dh y p e r g l y c e m i ai n
contrast to the normal ZL rats. As shown in Table 2, the
untreated ZDF rats had a more than fourfold increase of
fastingbloodglucoselevelsandincreasedHbA1clevels.Body
weightsofthevehicle-treatedZDFratswereelevatedapprox-
imately 80% compared to the normal ZL rats. KIOM-79
induced a minor decrease of blood glucose levels but did not
aﬀect HbA1c levels or body weight.
3.3. Cataract Formation. At the end of the thirteen-week
study, the lens opacity score of vehicle-treated ZDF rat
lenses was more than 3 (Figure 1). In normal ZL rats, no
lenses displayed cataract formation (score 0). However, theEvidence-Based Complementary and Alternative Medicine 5
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Figure 3: AGE accumulation. (A) Immunohistochemical localization of AGEs in lens from a normal Zucker lean rat (ZL), vehicle-treated
ZDF rat (ZDF) and ZDF rat treated with KIOM-79 (KIOM-79). A strong AGE immunoreactivity was observed in the cytoplasm of LECs
and lens ﬁbers of vehicle-treated ZDF rats. In contrast, immunoreactivity in lenses of KIOM-79-treated ZDF rats was decreased. X400
magniﬁcation. (B) Quantitative analysis of AGE immunoreactive intensity. (C) Western blot analysis of AGEs. Values in the bar graphs
represent means ± SE, n = 8. ∗P<. 01 versus normal ZL rats, #P<. 01 versus vehicle-treated ZDF rats.6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: The expression pattern of iNOS. (a) Immunohistochemical localization of iNOS protein. iNOS immunoreactivity (arrow) was
observed in the cytoplasm of LECs of diabetic lenses. The immunoreactivity in KIOM-79-treated rats was decreased in its intensity. ZL:
normal Zucker lean rat; ZDF: vehicle-treated ZDF rat; KIOM-79: ZDF rat treated with KIOM-79. X400 magniﬁcation. (b) Quantitative
analysis of iNOS protein signal intensity. Values in the bar graphs represent means ± SE, n = 8. ∗P<. 01 versus normal ZL rats, #P<. 01
versus vehicle-treated ZDF rats.
Table 2: Metabolic and physical parameters.
ZL ZDF KIOM-79
Body weight (g) 338.5 ±40.5 433.2 ± 69.4∗ 414.6 ±45.0
Blood glucose (mg/dl) 92.9 ±10.8 489.8 ±38.0∗ 391.7 ±113.2†
HbA1c (%) 3.7 ±0.17 .88 ± 1.3∗ 7.1 ±0.6
ZL: normal Zucker lean rats, ZDF: vehicle-treated Zucker diabetic fatty rats,
and KIOM-79: Zucker diabetic fatty rats treated with KIOM-79 (50mg/kg
bodyweight).Alldatawereexpressedasmean ±SD. ∗P<. 01versusnormal
ZL rats, †P<. 05 versus untreated ZDF rats.
administration of KIOM-79 to ZDF rats decreased the score
of lens opacity to 1.16. This result indicated that KIOM-79
reduced the development of cataracts in ZDF rats.
3.4. Apoptosis of LECs. In TUNEL assays, the lens sec-
tions from vehicle-treated ZDF rats showed many TUNEL-
positive cells in the anterior epithelial and equatorial
regions (Figure 2(a)). In immunoﬂuorescence staining, the
expression of cleaved caspase-3 protein was signiﬁcantly
increased 7.0-fold higher than normal ZL rat expression
patterns (Figures 2(b) and 2(d)). This result suggests that
a portion of the LECs underwent apoptosis under diabetic
conditions. This enhanced apoptotic cell death in ZDF
rats was signiﬁcantly suppressed, by 71%, with KIOM-79
treatment (Figure 2(c)).
3.5. AGE Accumulation in LECs. We next examined the
accumulation of AGEs in LECs by immunohistochemistry
and western blot analysis. As shown in Figures 3(a) and 3(b),
a striking increase in the immunoreactivity of AGEs was
observed in cataractous lenses of vehicle-treated ZDF rats.
Compared with normal ZL rats, this staining was observed
in the cytoplasm of LECs and in the deeper regions of
cortical ﬁbers. By western blotting analysis, the multiple and
intensive bands were detected in cataractous lenses of the
ZDF rats. The expression of AGEs was 2.7-fold higher in
the ZDF rat than that in the normal ZL rats (Figure 3(c)).Evidence-Based Complementary and Alternative Medicine 7
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Figure 5: Distribution of NF-κB in LECs detected by southwestern histochemistry. (a) Representative photomicrograph of lens from a
normal Zucker lean rat (ZL), vehicle-treated ZDF rat (ZDF), and ZDF rat treated with KIOM-79 (KIOM-79). Positive signals (arrow) for
activated NF-κB were mainly detected in nuclei of LECs of the vehicle-treated ZDF rat. X400 magniﬁcation. (b) Quantitative analysis of
positive cells in LECs. Values in the bar graphs represent means ± SE, n = 8. ∗P<. 01 versus normal ZL rats, #P<. 01 versus vehicle-treated
ZDF rats.
Hyperglycemia
AGEs
NF-κB
iNOS
Lens epithelial cell apoptosis
diabetic cataract
KIOM-79
Figure 6: Proposed mechanism for the protective eﬀect of KIOM-
79 against lens epithelial cell apoptosis in Zucker diabetic fatty rats.
However, the treatment of KIOM-79 reduced the AGEs
deposited in LECs and cortical ﬁbers.
3.6. Expression of iNOS in LECs. The localization of iNOS
protein was detected by immunohistochemistry. In catarac-
tous lenses of vehicle-treated ZDF rats, iNOS was markedly
expressed in the cytoplasm of LECs compared with normal
ZDF rat lenses. However, a remarkable reduction in the
immunoreactivity of iNOS was observed in LECs of KIOM-
79-treated rats (Figure 4(a)). In quantitative analysis, the
intensity of iNOS was increased ﬁvefold in vehicle-treated
ZDF rats compared to normal ZL rats. This change was
reduced by 63% with KIOM-79 treatment (P<. 01)
(Figure 4(b)).
3.7. Activation of NF-κBi nL E C s .NF-κBa c t i v i t yw a s
detected by southwestern histochemistry. This technique
allows the localization of the activated nuclear factor in8 Evidence-Based Complementary and Alternative Medicine
the cellular nucleus. Using this southwestern histochemistry
method, we observed that a marked NF-κBa c t i v i t yw a s
mainly found in the LEC nuclei of vehicle-treated ZDF rats
(Figure 5(a)). However, in the normal ZL rats, the signals
of activated NF-κB were rarely detected. Moreover, mor-
phometric analysis showed that the expression of activated
NF-κB in vehicle-treated ZDF rats was 6.0-fold higher than
normal ZL rats whereas KIOM-79 signiﬁcantly inhibited the
expression of activated NF-κBb y6 0 % ,w h e nc o m p a r e dt o
vehicle-treated ZDF rats (Figure 5(b), P<. 01).
4. Discussion
ApoptosisofLECsinducedbyultravioletradiation,oxidative
stress and hyperglycemia is associated with cataractogenesis
[3, 4]. In addition, the inhibition of LEC apoptosis has been
shown to reduce the formation of cataract [4, 31]. Therefore,
identiﬁcation of a treatment which blocks LEC apoptosis
and prevents cataract formation would present a potential
therapeutic strategy for diabetic cataract.
Inthisstudy,todeterminethepreventiveeﬀectofKIOM-
79 on LEC apoptosis, ZDF rats were treated with KIOM-
79 for 13 weeks. The ZDF rat is one of the attractive
models for type 2 diabetes based on its impaired glucose
tolerance caused by an inherited insulin-resistance gene.
The ZDF rats exhibited hyperglycemia and diabetic cataract
at 21 weeks old, which is in agreement with previous
reports [32]. In our previous study, serum AGE levels were
signiﬁcantly increased, and AGEs were highly accumulated
in the glomeruli and tubulointerstitium of 20-week-old ZDF
rats [33] .I nZ D Fr a t sa t2 1w e e k so fa g e ,A G E sw e r e
accumulated in LECs of cataractous lenses. These LECs with
increased AGEs underwent apoptosis under diabetic condi-
tions. Moreover, both the expression of iNOS and activation
of NF-κB in LECs were markedly increased during cataract
development.Interestingly,oraladministrationofKIOM-79,
a mixture of the 80% ethanol extract of parched Puerariae
radix, gingered Magnoliae cortex, Glycyrrhizae radix, and
Euphorbiae radix, prevented the enhanced apoptosis, AGE
accumulation, iNOS expression, and NF-κBa c t i v a t i o ni n
LECs.
We identiﬁed four major compounds (magnolol, hon-
okiol, glycyrrhizin, and puerarin) in KIOM-79. Each com-
ponent is considered to have antidiabetic eﬀects [29, 34–36].
Furthermore, it was previously reported that puerarin con-
fers a protective eﬀect against apoptosis in diabetic rat LECs
[37]. Magnolol prevents oxidized low density lipoprotein-
(oxLDL-) induced vascular endothelial apoptosis. Hon-
okiol suppresses NF-κB activation, and NF-κB-regulated
gene expression through the inhibition of IKKs [38]a n d
attenuates oxLDL-induced apoptosis in vascular endothelial
cells [39]. Glycyrrhizin inhibits 3-morpholinosydnonime-
induced apoptosis in lung epithelial cells [40]. Therefore, the
anti-apoptotic activity of KIOM-79 against diabetes-induced
LEC apoptosis may be considered to be due to the eﬀects of
these compounds.
NO is synthesized from L-arginine by NO synthase.
Inducible NO synthase (iNOS), one of the three isoforms
of NOS, is induced by various cytokines and AGEs [14, 15].
The induction of iNOS results in sustained and upregulated
release of excessive amounts of NO, which is cytotoxic to
neighboring cells [16, 17]. NO is also known to inﬂuence
apoptosis in a variety of models [41]. In several ocular dis-
eases, such as uveitis, retinitis, and glaucoma, the alteration
of iNOS and abnormal production of NO were observed
[18,19].ThelevelsofNOinthevitreousbodywereincreased
in diabetic retinopathy and traumatic cataract [42, 43]. The
apoptosis of human LECs stimulated by lipopolysaccharide
is accompanied by iNOS induction [44]. Moreover, an iNOS
inhibitor attenuates cataract formation in vitro. In contrast,
an NO generator accelerates cataract formation [22]. These
ﬁndings support the hypothesis that iNOS plays a key role in
controlling LEC function and apoptosis.
NF-κB is a multiprotein complex that can activate many
kinds ofgenesinvolved incellularfunctions.Inunstimulated
cells, NF-κB resides in the cytoplasm. Pathogenic stimuli
allow NF-κB to enter the nucleus where NF-κB binds
to DNA recognition sites in regulatory regions of target
genes [45–47]. The interaction of AGEs and their receptors
(RAGE) leads to NF-κBa c t i v a t i o n[ 48]. NF-κBa c t i v a t i o n
stimulated by the AGE/RAGE interaction contributes to
the development of diabetic ocular complications, such as
diabetic retinopathy and lacrimal gland dysfunction [12, 49–
51]. AGEs induce a dose-dependent activation of NF-κBi n
LECsinvitro[9].Moreover,NF-κBcaninducetheexpression
of iNOS mRNA through NF-κB binding sites in the iNOS
promoter [52–56].
At present, KIOM-79 induced only a minor decrease
of blood glucose levels and had no eﬀect on body weight
or HbA1c. However, KIOM-79 prevented lens opacity and
signiﬁcantly inhibited apoptosis, AGE accumulation, NF-κB
activation, and iNOS induction in LECs when compared
with vehicle-treated ZDF rats. Thus, these results strongly
suggest that the anticataract eﬀect of KIOM-79 is unrelated
to lowering blood glucose but it is due to the inhibition
of LEC apoptosis and AGE accumulation in the lenses of
ZDF rats. Our previous studies also showed that KIOM-
79 had an inhibitory eﬀect of AGE formation in vitro and
reduced AGE accumulation in the kidneys of STZ-induced
diabetic rats, as well as, in the retinas of db/db mice [24,
27]. KIOM-79 has also been shown to prevent apoptosis of
pancreatic betacells through the inhibition of the generation
of reactive oxygen species [26]. In addition, KIOM-79
reduces the production of nitrite in lipopolysaccharide-
stimulated murine macrophages [23].
Taken together, our results demonstrated a preventive
eﬀect of KIOM-79 on the formation of diabetic cataract
observed in ZDF rats. This ﬁnding suggests that the mech-
anism of KIOM-79 may be associated, in part, with the
inhibitionofAGEaccumulation.However,lensopaciﬁcation
is a complex phenomenon. Glycation represents only one of
the contributory factors in lens opaciﬁcation. Other factors,
such as the polyol pathway and oxidative stress have also
been implicated in the development of diabetic cataract
[1]. Therefore, it remains to be clariﬁed whether KIOM-
79 also provides an aldose reductase inhibiting activity or
antioxidant action.Evidence-Based Complementary and Alternative Medicine 9
In summary, KIOM-79 successfully prevented lens opac-
ity in ZDF rats. KIOM-79 also had an anti-apoptotic
eﬀect on LECs via the suppression of AGE accumulation
and its related signals including NF-κB activation, and
iNOS expression (Figure 6). Taken together, these results
indicate that treatment with KIOM-79 could be a valuable
therapeutic tool for diabetic cataract.
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